The Oncology Institute, Inc. (STLN) — Capital Reinvestment Ratio
Latest as of June 2026:
0.08x
The Oncology Institute, Inc. (STLN) has a Capital Reinvestment Ratio of 0.08x as of June 2026, meaning it reinvests 0% of its operating cash flow ($11.94 Million) in capital expenditures ($908.00K). See STLN equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
0.08x
Capex / Operating Cash Flow
Operating Cash Flow
$11.94 Million
USD
Capital Expenditures
$908.00K
USD
Data as of
Jun 2026
Most recent filing
Annual Capital Reinvestment Ratio for The Oncology Institute, Inc. (None–None)
Year-by-year Capital Reinvestment Ratio for The Oncology Institute, Inc. from None to None. For the full cash flow conversion analysis, see STLN operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow